Quick answer: Ozempic and Wegovy are one medicine, semaglutide from Novo Nordisk, sold under two FDA labels. Ozempic treats type 2 diabetes with a weekly pen that tops out at 2 mg (plus daily tablets), and its label adds heart and kidney protection for people with diabetes. Wegovy is for weight management: a weekly pen up to 2.4 mg, the 7.2 mg Wegovy HD pen and a daily pill, with heart and MASH liver approvals. When the STEP 2 trial gave adults with type 2 diabetes either dose, they lost 9.9% of body weight on Wegovy's 2.4 mg and 7.2% on 1 mg, an Ozempic dose. Novo charges self-pay patients $349 a month for most pen doses of either brand; Ozempic 2 mg is $499 and Wegovy HD $399.
Ozempic and Wegovy are brand-name, prescription GLP-1 receptor agonists, and both contain semaglutide. The difference is the label: which disease each is approved for, the doses its pens deliver, and therefore how insurers treat it. Here the two labels sit side by side, including the newer pills and the 7.2 mg dose. Comparing semaglutide with tirzepatide instead? See tirzepatide vs semaglutide or Zepbound vs Wegovy.
- Same molecule, different jobs: Ozempic is labelled for adults with type 2 diabetes, Wegovy for weight management in adults and teens from 12.
- STEP 2 (1,210 adults with type 2 diabetes and overweight, 68 weeks): 9.9% average weight loss on semaglutide 2.4 mg (Wegovy's dose), 7.2% on 1 mg (an Ozempic dose), 3.3% on placebo.
- NovoCare self-pay: either pen $199 for two intro fills, then $349; Ozempic 2 mg $499, Wegovy HD $399; both pills from $149.
Ozempic vs Wegovy: At a Glance
| Ozempicsemaglutide, diabetes label · Novo Nordisk | Wegovysemaglutide, weight label · Novo Nordisk | |
|---|---|---|
| Approved for | Type 2 diabetes in adults: glucose control, fewer heart attacks and strokes for those with heart disease, slower kidney decline for those with chronic kidney disease (label) | Weight reduction and maintenance in adults and ages 12+; heart-risk reduction in adults with heart disease and obesity or overweight (Mar 2024); MASH with moderate-to-advanced fibrosis (Aug 2025, accelerated approval) |
| Who the label covers | Adults diagnosed with type 2 diabetes, whatever their weight | Generally a BMI of 30 or above, or 27 and above with a weight-related condition; diabetes not required |
| Injections | One multi-dose pen per month, set to 0.25/0.5 mg, 1 mg or 2 mg | Single-dose pens 0.25–2.4 mg, a FlexTouch pen (4 doses of 2.4 mg) and the 7.2 mg Wegovy HD pen |
| Dose steps | Begins at 0.25 mg, moves to 0.5 mg in week 5; 1 mg and then 2 mg follow only for blood-sugar reasons | 0.25, 0.5, 1 and 1.7 mg for 4 weeks each, then 2.4 mg (or 1.7 mg); 7.2 mg only after 4+ weeks on 2.4 mg |
| Top weekly dose | 2 mg | 2.4 mg; 7.2 mg as Wegovy HD |
| Daily pill | Ozempic tablets 1.5, 4 and 9 mg, for type 2 diabetes (label) | Wegovy pill 1.5, 4, 9 and 25 mg, for weight and heart risk (approved Dec 2025) |
| Self-pay from | $199 intro fills, then $349 a month to 1 mg or $499 at 2 mg; tablets from $149 | $199 intro fills, then $349 a month to 2.4 mg; HD $399; pill from $149 |
Ozempic vs Wegovy results: the STEP 2 dose comparison
Because the molecule is the same, the real question is dose. STEP 2 is the one trial that randomized adults with type 2 diabetes and overweight to semaglutide 2.4 mg (Wegovy's dose), 1 mg (an Ozempic dose) or placebo, for 68 weeks. It compared doses, not the branded pens as sold, and Ozempic 2 mg has never been tested against Wegovy.
| Result | Ozempicsemaglutide, diabetes label · Novo Nordisk | Wegovysemaglutide, weight label · Novo Nordisk |
|---|---|---|
| Average weight loss at 68 weeks, adults with type 2 diabetesCounting: everyone randomized, observed during the trial whether or not they kept taking the drug (in-trial) | 7.2%STEP 2, 1,210 people, 68 weeks; 1 mg; placebo 3.3% | 9.9%STEP 2, 1,210 people, 68 weeks; 2.4 mg |
| Lost 5% or more of body weight, adults with type 2 diabetesCounting: everyone randomized, observed during the trial whether or not they kept taking the drug (in-trial) | 57.1%STEP 2, 1,210 people, 68 weeks; 1 mg; 217 of 380 measured | 68.8%STEP 2, 1,210 people, 68 weeks; 2.4 mg; 267 of 388 measured |
| Average weight loss, adults without diabetesCounting: all randomized participants, stoppers included (treatment-policy) | Not studied | 14.9%STEP 1, 1,961 people, 68 weeks; 2.4 mg; placebo 2.4% |
STEP 2 figures are the observed averages posted on ClinicalTrials.gov; the Lancet paper's model-based estimate is 9.6% for 2.4 mg versus 3.4% for placebo. The third row is a different trial in people without diabetes, who tend to lose more on semaglutide, so set it apart from the STEP 2 rows. Wegovy HD 7.2 mg averaged 18.7% in STEP UP, also without diabetes. None of this applies to compounded semaglutide.
Same molecule, different label: why two brand names?
The FDA approves a product for specific uses at specific doses. Novo Nordisk first developed semaglutide for type 2 diabetes and sold it as Ozempic; it later ran the STEP trials of a higher dose for weight management and got that approved as a separate product, Wegovy. Each brand has its own pens, dose ladder, prescribing information and price list, and a pharmacy cannot swap one for the other on a prescription. The pills follow the same split: Ozempic tablets for diabetes, the Wegovy pill for weight.
The label also drives coverage. Ozempic sits in the diabetes part of most formularies, usually with the diagnosis checked at prior authorization, while Wegovy falls under weight-management benefits that many employers exclude.
What does the higher dose mean for weight loss?
STEP 2 showed a dose effect within the same drug: 2.4 mg produced more weight loss than 1 mg in people with type 2 diabetes (9.9% against 7.2%), with a few more stomach complaints (see below). Wegovy HD pushes the dose to 7.2 mg for people already on 2.4 mg: in STEP UP, adults without diabetes averaged 18.7% on 7.2 mg (Lancet Diabetes & Endocrinology 2025). Ozempic stops at 2 mg because its ladder was built for blood sugar; the SUSTAIN FORTE trial added the 2 mg step after it lowered A1C by 2.1 points versus 1.9 on 1 mg (Ozempic label), not for weight.
Ozempic is sometimes prescribed off-label for weight. Whether that fits is the prescriber's call, and coverage for it is uncommon; Wegovy is the semaglutide product approved and dosed for weight management.
Heart protection: SUSTAIN 6 for Ozempic, SELECT for Wegovy
Each brand earned its heart claim in a different population. Wegovy's SELECT trial followed 17,604 adults with heart disease and overweight but no diabetes for a median of 41.8 months: major cardiac events fell from 8.0% on placebo to 6.5%, a 20% lower risk (Wegovy label). Ozempic's claim comes from SUSTAIN 6, run in people with type 2 diabetes (Ozempic label), and its kidney claim from FLOW, in diabetes with chronic kidney disease (NEJM 2024).
The semaglutide pills: Ozempic tablets and the Wegovy pill
Both brands now come as a once-daily tablet, swallowed first thing, fasting, with no more than 4 oz of plain water and a 30-minute wait before breakfast or other medicines. Ozempic tablets (1.5, 4 and 9 mg) share a label with Rybelsus and are approved for type 2 diabetes; the Wegovy pill (1.5, 4, 9 and 25 mg) is approved for weight reduction and heart-risk reduction. Self-pay, both start at $149 a month. Pills and injections do not convert milligram for milligram. More: oral vs injectable semaglutide.
How does Ozempic vs Wegovy compare to tirzepatide options?
Tirzepatide is a dual GIP/GLP-1 receptor agonist sold as Mounjaro (diabetes) and Zepbound (weight). Against semaglutide it has shown higher average weight loss in some head-to-head data: SURPASS-2 in type 2 diabetes against Ozempic 1 mg, and SURMOUNT-5 in obesity against Wegovy's dose. Brand-by-brand: Mounjaro vs Ozempic, Zepbound vs Ozempic (also Zepbound vs Ozempic by label), tirzepatide vs semaglutide, Foundayo vs Zepbound, and for compounded versions, tirzepatide-based options.
Ozempic or Wegovy: who each label fits
| If you… | What the labels and trials point to |
|---|---|
| Need treatment for type 2 diabetes itself | Ozempic is the one labelled for it; Wegovy is not approved to treat diabetes, though STEP 2 enrolled people with it |
| Have kidney disease from type 2 diabetes | Ozempic, which carries the FLOW kidney approval |
| Carry extra weight but have no diabetes | Wegovy is the semaglutide product approved for weight management |
| Have heart disease plus type 2 diabetes | Ozempic, from the SUSTAIN 6 trial |
| Have heart disease plus obesity or overweight, no diabetes | Wegovy pen or pill, from the SELECT trial |
| Have MASH with fibrosis | Wegovy pen (accelerated approval) |
| Are a teenager | Wegovy pen is approved from age 12; Ozempic is for adults |
| Want a pill instead of a shot | Ozempic tablets for diabetes, the Wegovy pill for weight |
Coverage usually follows the label, so check both before deciding: see our guide to insurance and GLP-1 medications and how to get GLP-1 coverage.
Ozempic vs Wegovy side effects
Same drug, so the same kinds of side effects, mostly stomach and gut, and more of them at higher doses. The first four rows come from each label's own placebo-controlled trials, in different people and at different doses; the last row is from STEP 2, where both doses ran in one trial.
| Side effect | Ozempicsemaglutide, diabetes label · Novo Nordisk | Wegovysemaglutide, weight label · Novo Nordisk |
|---|---|---|
| Nausea | 20.3% (6.1%) | 44% (16%) |
| Diarrhea | 8.8% (1.9%) | 30% (16%) |
| Vomiting | 9.2% (2.3%) | 24% (6%) |
| Constipation | 3.1% (1.5%) | 24% (11%) |
| Any stomach or gut side effect, STEP 2 (same trial) | 57.5% at 1 mg | 63.5% at 2.4 mg (placebo 34.3%) |
The two labels share one boxed warning, on thyroid C-cell tumors, and the same exclusion for anyone whose own or family history includes medullary thyroid cancer or MEN 2. Shared precautions cover pancreatitis, gallbladder trouble, dehydration-related kidney injury, hypoglycemia alongside insulin or sulfonylureas, allergy, diabetic eye complications and aspiration under anesthesia. Wegovy's label also lists a raised heart rate, and at 7.2 mg skin-sensation changes (dysesthesia) were more common. Older label PDFs from the FDA: Ozempic (2025), Wegovy (2025).
How much does Ozempic vs Wegovy cost in 2026?
NovoCare sells both brands self-pay at nearly the same prices; the gap is at the top doses, where Ozempic 2 mg costs more than any Wegovy pen below HD:
| Option | Month 1 | Usual maintenance month | First-year estimate | Source |
|---|---|---|---|---|
| Ozempic 0.25 to 1 mg | $199 a pen for the first two (new patients) | $349 a month | $3,888 | NovoCare Ozempic guide |
| Ozempic 2 mg | Not a starting dose | $499 a month | $5,238 | NovoCare Ozempic guide |
| Ozempic pill | $149 (1.5 mg) | $199 (4 mg) or $299 (9 mg) | $3,338 | NovoCare Ozempic guide |
| Wegovy pen, up to 2.4 mg | $199 a pen for the first two (new patients) | $349 at any dose to 2.4 mg | $3,888 | NovoCare Wegovy |
| Wegovy HD 7.2 mg pen | Not a starting dose | $399 | Not estimated† | NovoCare Wegovy |
| Wegovy pill | $149 (1.5 mg) | $299 at 9 or 25 mg | $3,338 | NovoCare Wegovy |
The first-year column is our arithmetic, summing 12 monthly fills at NovoCare's list of cash prices; drug cost only. Either pen at standard doses: two fills at $199 then ten at $349. Ozempic 2 mg row: those two intro fills and a 1 mg month, then nine at $499. Pills: 1.5 mg and 4 mg months, then ten at the 9 mg (Ozempic) or 9 or 25 mg (Wegovy) price. A pen fill lasts four weeks, so twelve fills fall about a month short of a calendar year. †Wegovy HD only follows at least 4 weeks on 2.4 mg. Both $199 offers close Dec 31, 2026.
With insurance: Novo's savings cards bring either brand to "as little as $25" for commercially insured patients whose plan covers it, saving at most $100 a month (Ozempic offer, Wegovy card); Medicare and Medicaid patients are excluded. Medicare: Part D plans can cover Ozempic for type 2 diabetes; for weight, the Medicare GLP-1 Bridge charges eligible members $50 a month for Wegovy (pen or pill) from July 1, 2026 through Dec 31, 2027, with prior authorization. HSA/FSA: prescribed GLP-1s are generally eligible for FSA/HSA reimbursement; check with your plan administrator. Brand by brand: Wegovy cost without insurance, Ozempic cost without insurance, and the GLP-1 cost guide. Telehealth companies' published cash prices are compared at joinnouri.com/weight-loss.
Switching from Ozempic to Wegovy
Both are semaglutide, but the pens and dose ladders differ and neither label gives a conversion. Wegovy's label starts at 0.25 mg and steps up every 4 weeks; whether someone already on Ozempic can start further up the ladder is the prescriber's decision, and insurance usually needs a new prior authorization under the weight-management benefit. Pills and injections don't map onto each other milligram for milligram either. Moving to tirzepatide instead: the semaglutide-to-tirzepatide switching guide.
Where compounded semaglutide fits
Some people buy compounded semaglutide through telehealth providers, made up by state-licensed 503A compounding pharmacies. Compounded semaglutide is not FDA-approved: no FDA review of its safety, effectiveness or quality has taken place, and it is a different product from Ozempic or Wegovy, so the STEP and SUSTAIN numbers on this page say nothing about it. The FDA explains its position on drug compounding and on GLP-1 receptor agonist safety and compounding concerns; for background on the class, see NIDDK. More: compounded semaglutide vs Wegovy and brand-name vs compounded GLP-1. For what compounded semaglutide costs next to the brand pens, see our semaglutide price comparison and our GLP-1 prices without insurance, ranked by monthly cost.
Related comparisons
- Zepbound vs Wegovy: SURMOUNT-5, prices and pens
- Tirzepatide vs Semaglutide: which GLP-1 is right for you?
- Zepbound vs Ozempic: differences, cost, and coverage
- Oral vs Injectable Semaglutide (2025)
- Compounded Semaglutide vs Wegovy: price, access, and legal status
- Brand-Name vs Compounded GLP-1: what to know
- GLP-1 cost guide 2026 (all options)
- Compare licensed providers
Frequently asked questions
Are Ozempic and Wegovy the same thing?
They contain the same drug, semaglutide from Novo Nordisk, but are separate FDA-approved products: Ozempic for type 2 diabetes (up to 2 mg weekly) and Wegovy for weight management (2.4 mg weekly, or 7.2 mg as Wegovy HD). The pens, dose steps, approved uses and coverage differ.
Which is better for weight loss, Ozempic or Wegovy?
Wegovy is the one FDA-approved for weight management, at higher doses. In STEP 2, adults with type 2 diabetes lost 9.9% of body weight on semaglutide 2.4 mg against 7.2% on 1 mg over 68 weeks.
Is Wegovy a higher dose than Ozempic?
Yes: Ozempic tops out at 2 mg a week, while Wegovy's maintenance dose is 2.4 mg (or 1.7 mg) and Wegovy HD is 7.2 mg. The pills differ too, with Ozempic tablets up to 9 mg a day and the Wegovy pill up to 25 mg.
Does insurance cover Wegovy and Ozempic the same way?
No: plans usually cover Ozempic for type 2 diabetes, while many exclude Wegovy or require prior authorization for weight management. Actual coverage depends on your plan.
Is there a cheaper version of semaglutide?
The Ozempic and Wegovy pills start at $149 a month self-pay through NovoCare, versus $349 for most pen doses (checked Oct 13, 2026). Compounded semaglutide sold by telehealth companies often costs less, but it is not FDA-approved and is not the same as Wegovy or Ozempic.
Can I switch from Ozempic to Wegovy for weight loss?
Switching takes a new prescription for Wegovy, and the starting dose and timing are your prescriber's call because the products don't convert milligram for milligram. Insurance often needs a separate prior authorization for Wegovy.
How much do Ozempic and Wegovy cost without insurance?
Through NovoCare, both pens are $349 a month after two $199 intro fills for new patients; Ozempic 2 mg is $499 and Wegovy HD 7.2 mg is $399. Both pills start at $149.
Why does Ozempic 2 mg cost more than Wegovy 2.4 mg?
Novo Nordisk sets self-pay prices by product and dose, not by milligram: its NovoCare price guides list Ozempic 2 mg at $499 a month and the Wegovy pen at $349 at any dose up to 2.4 mg.
Is the Ozempic pill the same as the Wegovy pill?
Both are daily semaglutide tablets taken fasting, but Ozempic tablets (1.5 to 9 mg) are approved for type 2 diabetes and the Wegovy pill (up to 25 mg) for weight management and heart-risk reduction.
Sources and references
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet 2021;397:971-984 (accessed Oct 13, 2026)
- STEP 2 on ClinicalTrials.gov (NCT03552757), observed results (accessed Oct 13, 2026)
- Wilding JPH et al., STEP-1: Once-Weekly Semaglutide in Adults with Overweight or Obesity, NEJM 2021;384:989-1002 (accessed Oct 13, 2026)
- Lincoff et al., SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, NEJM 2023 (accessed Oct 13, 2026)
- Wharton S et al. Semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes & Endocrinology 2025 (accessed Oct 13, 2026)
- FLOW kidney-outcomes trial of semaglutide, NEJM 2024 (accessed Oct 13, 2026)
- Ozempic injection prescribing information (DailyMed, June 2026) (accessed Oct 13, 2026)
- Ozempic and Rybelsus tablets prescribing information (DailyMed) (accessed Oct 13, 2026)
- Wegovy injection and tablets prescribing information (DailyMed, June 2026) (accessed Oct 13, 2026)
- FDA news release: Wegovy heart-risk approval, Mar 8, 2024 (accessed Oct 13, 2026)
- FDA: Wegovy approved for MASH, Aug 15, 2025 (accessed Oct 13, 2026)
- Novo Nordisk release on the Wegovy pill approval, Dec 22, 2025 (accessed Oct 13, 2026)
- NovoCare Ozempic price guide (pill and pen, May 2026) (accessed Oct 13, 2026)
- NovoCare Ozempic savings offer (accessed Oct 13, 2026)
- NovoCare Wegovy pricing (pen, HD and pill) (accessed Oct 13, 2026)
- NovoCare Wegovy savings card (accessed Oct 13, 2026)
- Centers for Medicare & Medicaid Services: GLP-1 Bridge (accessed Oct 13, 2026)
This page compares published trials, FDA labels and makers' price pages; it is not medical advice, and a licensed prescriber decides which drug and dose fit you. Trial results are for the FDA-approved branded drugs only. Nouri is a publisher; it does not prescribe or sell any medication, and it is not affiliated with Eli Lilly or Novo Nordisk. Facts checked Oct 13, 2026; prices change, so confirm at the source.
Disclosure: Nouri may earn a commission when you sign up with some of the providers we link to. It doesn't change what you pay or how we rank providers. No drug maker paid for this comparison. Full disclosure.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Nouri is an independent publisher: it does not prescribe, review patient assessments, or sell medication. Talk to a licensed clinician before starting or changing any medication or treatment.
Compare licensed GLP-1 providers
Published cash prices side by side, with the month we checked them and a link to each provider's own site. Nouri doesn't prescribe or sell medication.